Podcasts about new england journal

Recently the Endocrine Society’s Bone and Mineral Special Interest Group discussed the importance of fracture liaison services and how they contribute to an improved quality of life for patients and cost saving for the facility. An important part of the discussion revolved around a recent perspective published in The New England Journal of Medicine titled, “Coordinating Multidisciplinary Care — Improving Outcomes after Fragility Fractures.” The article notes that despite the benefits of fracture liaison services, the lack of reimbursement for those services in the United States is a significant financial barrier, rendering the service underutilized. The article further states that the global burden of hip fractures is expected to double over the next few decades. Are we looking at an impending crisis? What role should fracture liaison services play in reducing treatment gaps and improving post-fracture care? Host Aaron Lohr talks with the three authors of that New England Journal of Medicine perspective: Nicola Napoli, MD, PhD, associate professor of endocrinology and metabolism at Campus Bio-Medico University of Rome, Italy; Peter Ebeling, AO, professor medicine at Monash University in Melbourne, Vic., Australia; and Douglas P. Kiel, MD, professor of medicine at Marcus Institute for Aging Research at Hebrew Senior Life. Show notes are available at https://www.endocrine.org/podcast/enp99 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Kann man den Hunger einfach wegspritzen? Und was passiert eigentlich, wenn du plötzlich keinen Appetit mehr hast?Die Medien sind voll von Mythen, Halbwissen und Marketing rund um Ozempic, Wegovy und anderen der sogenannten „Abnehmspritzen“. In dieser Episode bekommst du den Überblick, den du brauchst – um Dir eine eigene Meinung zu bilden.Du erfährst:warum viele Menschen nicht zunehmen, obwohl sie mehr essen – und andere schon bei normalen Portionen zunehmen,was GLP-1-Wirkstoffe mit Spielsucht, Alkohol und impulsivem Verhalten zu tun haben,warum viele Patienten nach dem Absetzen der Spritze schneller wieder zunehmen, als sie abgenommen haben,und warum es gefährlich sein kann, unter diesen Medikamenten zwar Gewicht zu verlieren – aber dabei Muskeln zu verbrennen statt Fett.Und wenn Du ohnehin sagst: „Spritze? Kommt für mich nicht infrage“, lohnt diese Episode – weil sie Dir hilft, den Mechanismus hinter Hunger, Sättigung und Gewohnheiten besser zu verstehen. Und damit auch Deinen eigenen Körper effektiver zu steuern.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Mehr zum Thema:Podcast: Folge 502: Ratgeber Nahrungsergänzung – mit Ernährungsmediziner Niels Schulz-RuhtenbergQuellen:Wilding, J. P. H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.Garvey, W. T. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091.Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.Ryan, D. H. & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194.Marx, N. et al. (2022). GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation, 146(24), 1882–1894.Lincoff, A. M. et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.Karakasis, P. et al. (2023). Effect of tirzepatide on renal function in type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism.Ida, S. et al. (2021). Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Current Diabetes Reviews, 17(3), 293–303.Wilding, J. P. H. et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Suppl. 1), A16–A17.Gorgojo-Martínez, J. J. et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine Research, 12(1).Tantawy, S. A. et al. (2017). Effects of physical activity and diet control to manage constipation in middle-aged obese women. Diabetes, Metabolic Syndrome and Obesity, 10, 513–519.Jastreboff, A. M. et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526.***Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

For too long, Alcohol Use Disorder (AUD) has been misunderstood as a failure of willpower—but science tells a different story. In this episode, we dive into the neurological basis of addiction, exploring how AUD rewires the brain and why overcoming it requires more than sheer determination. We'll debunk myths, highlight the role of medical and psychological support, and offer insight into what real recovery looks like. If you've ever wondered why quitting alcohol feels impossible for some, this episode is for you.Find out about the free resources and all our books available at winspress.com.******************************************************************************************References for today's episode:Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760-773. https://doi.org/10.1016/S2215-0366(16)00104-Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363-371. https://doi.org/10.1056/NEJMra151148Goldstein, R. Z., & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. Nature Reviews Neuroscience, 12(11), 652-669. https://doi.org/10.1038/nrn311Bechara, A. (2005). Decision making, impulse control and loss of willpower to resist drugs: A neurocognitive perspective. Nature Neuroscience, 8(11), 1458-1463. https://doi.org/10.1038/nn158McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA, 284(13), 1689-1695. https://doi.org/10.1001/jama.284.13.168.Marlatt, G. A., & Donovan, D. M. (2005). Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. Guilford Press.

Microsoft says its Artificial Intelligence Diagnostic Orchestrator is showing great progress in diagnosing illnesses, and works faster than human doctors when given data from the New England Journal of Medicine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright break down the essentials of a true metabolic workup. This episode moves beyond social media diet trends and digs into the science behind comprehensive lab panels, what they measure, and why they matter for your whole-body health. Dr. Cooper explains how to interpret common and advanced metabolic markers—like blood sugar, insulin, cholesterol, hormone levels, and more—while Andrea and Mark share personal insights into the power of understanding your metabolic baseline. If you're concerned about weight, diabetes, or just want to know your numbers, this episode gives you the knowledge to talk confidently with your healthcare provider.Key Takeaways:A whole-body metabolic approach goes beyond just weight or blood pressure—comprehensive lab work (plus family history) is essential to uncover risks or dysfunction early.Standard blood panels provide useful clues (glucose, cholesterol, liver, kidney, blood pressure), but advanced tests (A1C, lipid particles, hormone levels, inflammation markers) round out the picture.Metabolic dysfunction is driven by factors far deeper than calories in/out—dieting and under-fueling can actually weaken metabolism over time.Medication for metabolic health is not a failure; it's a science-backed intervention. Early and accurate testing allows for better, evidence-based treatment.Don't ignore “borderline” results—addressing issues early is easier and more effective than trying to reverse advanced dysfunction later.Personal Stories & Practical Advice:Andrea recounts her life-changing journey from endless dieting to real answers through complete metabolic testing and individualized treatment.Mark highlights the need for patients to advocate for themselves and ask for more than just the standard panel at annual exams.References:Diet Failure Rate• Mann, T., et al. (2007). "Medicare's search for effective obesity treatments: diets are not the answer." American Psychologist, 62(3), 220-233• Anderson, J. W., et al. (2001). "Long-term weight-loss maintenance: a meta-analysis of US studies." American Journal of Clinical Nutrition, 74(5), 579-584Persistent Metabolic Adaptation• Fothergill, E., et al. (2016). "Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition." Obesity, 24(8), 1612-1619• Rosenbaum, M., & Leibel, R. L. (2010). "Adaptive thermogenesis in humans." International Journal of Obesity, 34(S1), S47-S55Long-Term Hormonal Disruption • Sumithran, P., et al. (2011). "Long-term persistence of hormonal adaptations to weight loss." New England Journal of Medicine, 365(17), 1597-1604• Rosenbaum, M., et al. (2005). "Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight." Journal of Clinical Investigation, 115, 3579-3586Weight Cycling Cardiovascular Risks• Montani, J. P., et al. (2006). "Weight cycling during growth and beyond as a risk factor for later cardiovascular diseases: the 'repeated overshoot' theory." International Journal of Obesity, 30(S4), S58-S66Resources:Connect with Dr. Emily Cooper on LinkedInConnect with Mark Wright on LinkedInConnect with Andrea Taylor on InstagramFat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.comScience is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org

In this episode of the Crux True Survival Story Podcast, hosts Julie Henningsen and Kaycee McIntosh recount the harrowing tale of a French family's dream vacation that turned into a nightmare at White Sands National Park in New Mexico. The episode delves into the extreme conditions and decisions that led to the deaths of David and Ornella Steiner, who sacrificed their lives to save their 9-year-old son amidst the park's unforgiving heat. Through expert insight and a step-by-step narrative, listeners gain a deeper understanding of the physiological and psychological challenges faced in such harsh environments, emphasizing the critical importance of preparation and caution when venturing into nature's most perilous landscapes. 00:00 Introduction to the Podcast 00:39 Setting the Scene: White Sands National Park 02:16 Meet the Steiner Family 04:46 The Fateful Hike Begins 08:38 The Harsh Realities of White Sands 13:50 Understanding Heat-Related Illnesses 16:40 A Mother's Sacrifice 18:01 Ruff Greens 19:12 A Heartbreaking Turn of Events 20:04 The Sunk Cost Mentality 21:05 Heat Exhaustion and Underestimation 23:20 The Family's Final Moments 25:09 The Rescue Operation 26:57 Aftermath and Reflections 28:09 Lessons from the Tragedy 30:33 The Essence of Parental Love 36:00 Final Thoughts and Takeaways 37:23 Podcast Outro and Listener Engagement   Email us! thecruxsurvival@gmail.com Instagram https://www.instagram.com/thecruxpodcast/ Get schooled by Julie in outdoor wilderness medicine! https://www.headwatersfieldmedicine.com/ References StrangeOutdoors.com - "The disturbing deaths of David and Ornella Steiner at White Sands Monument" (July 21, 2024) CNN - "French couple who died in desert gave son extra water, sheriff said" (August 11, 2015) The Washington Post - "French parents who died on New Mexico trail saved son's life by giving him their water, sheriff says" (August 8, 2015) Outside Online - "Couple Dies Hiking in White Sands" (August 2015) TIME - "Boy's Life Spared When Parents Sacrifice Water to Save Him in Desert" (August 11, 2015) France24 - "French couple die in US desert, nine-year-old son rescued" (August 8, 2015) CNN - "French couple dies in New Mexico desert; son survives" (August 10, 2015) Christian Science Monitor - "French couple dies in New Mexico desert, but saves son by giving him water" (August 11, 2015) Albuquerque Journal - "French couple die during midday White Sands hike" (August 7, 2015) ABC7 Chicago - "Sheriff: French pair who died in US desert likely saved son" (August 9, 2015) Yahoo Finance - "French hikers die in US desert, son survives" (August 8, 2015) Medical Sources: 12. Cleveland Clinic - "Heat Stroke: Symptoms, Treatment & Recovery" (2021) 13. NHS - "Heat exhaustion and heatstroke" 14. Healthline - "Heat Stroke vs. Heat Exhaustion: What's the Difference?" (May 26, 2023) 15. PMC/NCBI - "Exertional heat stroke: pathophysiology and risk factors" 16. StatPearls/NCBI - "Heat Stroke" 17. New England Journal of Medicine - "Heatstroke"

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Effects of Combining Coronary Calcium Score With Treatment on PlaqueProgression in Familial Coronary Artery Disease A Randomized Clinical Trial JAMA 2025. Discussion by:Guest: Michael J. Blaha, MD, MPHProfessor of Cardiology and Epidemiology and presently serves as theDirector of Clinical Research for the Johns Hopkins Ciccarone Center for thePrevention of Cardiovascular DiseaseDirector of the Cardiometabolic ClinicProgram Director for the Preventive Cardiology Fellowship.2. Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimer's Dement. 2025. Discussion by:Guest:Michael Devano, DO Attending Family Physician Christiana Care Health System3. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England Journal of Medicine. Discussion by:Guest:Joseph Gonnella, MD Resident– Family MedicineResidency Program, Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Transcript [Music] For Food Safety in a Minute, I'm Susie Craig. It may surprise you, scientists don't know that much about the naturally occurring chemical make-up of our food. Nutrition research has historically focused on protein, carbohydrates, fats, vitamins and minerals. Though researchers have identified 139,000 molecules in food, scientists do not know if they are absorbed, how they are metabolized in our bodies, to which protein they bind, and what cellular processes they affect. Consider the complexity of the chemicals and food along with the complexity of how our bodies metabolize and use those chemicals. With research focused on chemical mapping of foods paired with artificial intelligence, it's possible nutritional science will be revolutionized, new drugs from food chemicals will be developed. Food is Medicine. From Washington State University Extension, this Food Safety in a Minute. [Music] Resources Menichetti, Giulia, A Barnabas and J. Loscalzo. Chemical Complexity of Food and Implications for Therapeutics. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMra2413243

Hvorfor er det så vanskelig å holde vekten, selv etter en vellykket slankekur?I denne episoden tar vi et ærlig og forskningsbasert dykk i hva som skjer i kroppen etter vekttap – og hvorfor det ikke bare handler om viljestyrke eller kalorikontroll. Monica og Alette deler egne erfaringer, siste forskning og praktiske biohacks du kan bruke for å skape varig vektnedgang og hormonell balanse.

¿La glucosamina realmente ayuda con el dolor articular o es solo otro suplemento sobrevalorado? En este episodio te explico qué dice la ciencia actual, quién podría beneficiarse de tomarla, quién debería evitarla y por qué tantas veces viene acompañada de condroitina. Además, te cuento sobre los suplementos para las articulaciones que han recibido alertas sanitarias por parte de COFEPRIS. Así que dale play, porque tu salud articular lo vale. Búscanos en: Spotify - https://spoti.fi/2PLIXFV Apple podcast - https://apple.co/31XRnfT Google podcast - https://bit.ly/3fN4YPf Ivoox - https://bit.ly/2QbM1LT y en YouTube búscanos como NutriEat Contigo https://bit.ly/32dTtbI ¡suscríbete y activa la campanita para que te lleguen todas las notificaciones! Dudas, comentarios o sugerencias...¡Escríbenos! L.N Carla Paola AM ⚕ Envíame un WhatsApp 55 6325 6115. Búscame en Facebook, X e Instagram como @Nut.CarlaPaola #NutrieatContigo ----------------------- Bibliografía Li, Z. H., Gao, X., Chung, H. F., Zhang, X., Tan, Y. T., Wang, Y., ... & Lv, J. (2019). Association of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. BMJ, 365, l1628. https://doi.org/10.1136/bmj.l1628 Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., ... & Williams, H. J. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine, 354(8), 795-808. https://doi.org/10.1056/NEJMoa052771 Wandel, S., Jüni, P., Tendal, B., Nüesch, E., Villiger, P. M., Welton, N. J., ... & Reichenbach, S. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ, 341, c4675. https://doi.org/10.1136/bmj.c4675 National Center for Complementary and Integrative Health (NCCIH). (2023). Glucosamine and Chondroitin for Osteoarthritis. U.S. Department of Health & Human Services. https://www.nccih.nih.gov/health/gluc... MedlinePlus. (n.d.). Glucosamine. U.S. National Library of Medicine. Retrieved May 6, 2025, from https://medlineplus.gov/druginfo/natu... Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). (2022). Alerta sobre productos engaño que utilizan ajo con supuestas cualidades curativas. https://www.gob.mx/cofepris/articulos... Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). (2021). Alerta sobre comercialización ilegal del producto Artri Ajo King. https://www.gob.mx/cofepris/articulos...

Still struggling with IBS symptoms, even after trying everything?   It might not be “just IBS.”   In the first episode of The Gut Show, Season 8, Dr. Mark Pimentel breaks down the connection between SIBO, IMO, ISO, and IBS, and what patients need to know about testing, treatment, and what's actually causing your symptoms.   We talked about breath tests, stool tests, probiotics, antibiotics (like Rifaximin + Neomycin), the meds that cause SIBO, and more.   Covered in this episode: Introducing Dr. Pimentel, MD [2:18] What is SIBO, ISO and IMO? [3:18] Should everyone with IBS do breath testing? [7:14] New guidelines that have come out [9:50] How should a patient navigate testing? [11:11] What about stool testing? [13:16] Negative test + symptoms or positive test without symptoms [16:50] What does normal mean? [18:44] Who does all 3 [20:39] Glucose vs Lactulose for the test [21:05] What causes these overgrowths? [21:52] The medication that WILL make you have SIBO [23:53] MAST cells, IBD, endometriosis [24:34] Treatment [32:07] Rifaximin [34:19] Any Statin or seaweed based treatment updates? [37:51] Neomycin [39:25] Elemental diet [41:23] What Dr. Pimentel wants for his patients [45:17] Probiotics [46:40] The role of metabolic disorders [48:22] Rapid fire questions [50:59]   Mentioned in this episode:  MASTER Method Membership Take the quiz: What's your poop personality?      Sponsors of The Gut Show:  FODZYME is the world's first enzyme supplement specialized to target FODMAPs. When sprinkled on or mixed with high-FODMAP meals, FODZYME's novel patent-pending enzyme blend breaks down fructan, GOS and lactose before they can trigger bloating, gas and other digestive issues. With FODZYME, enjoy garlic, onion, wheat, Brussels sprouts, beans, dairy and more — worry free! Discover the power of FODZYME's digestive enzyme blend and eat the foods you love and miss. Visit fodzyme.com and save 20% off your first order with code THEGUTSHOW. One use per customer. Gemelli Biotech offers trusted, science-backed at-home tests for conditions like SIBO, IMO, ISO, and post-infectious IBS.  Their Trio-Smart breath test measures all three key gases: hydrogen, methane, and hydrogen sulfide to detect different forms of microbial overgrowth. And for those with IBS symptoms, IBS-Smart is a simple blood test that can confirm post-infectious IBS with clinical accuracy. You simply order the test, complete it at home, send it back, and get clinically backed results in about a week that you can take to your provider!  Find out which tests are right for you at getgutanswers.com and use code ERINJUDGE25 to save $25 on your order!   About our speaker: Mark Pimentel, MD, FRCP(C), is a Professor of Medicine at Cedars-Sinai and Professor of Medicine and of Gastroenterology through Geffen School of Medicine. Dr. Pimentel is also the Executive Director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, an enterprise of physicians and researchers dedicated to the study of the gut microbiome in order to develop effective diagnostic tools and therapies to improve patient care. As a physician and researcher, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical investigations of irritable bowel syndrome (IBS) and the relationship between gut flora composition and human disease. This research led to the first ever blood tests for IBS, ibs-smart™, the only licensed and patented serologic diagnostic for irritable bowel syndrome. The test measures the levels of two validated IBS biomarkers, anti-CdtB and anti-vinculin. A pioneering expert in IBS, Dr. Pimentel's work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has presented at national and international medical conferences and advisory boards. He is a diplomate of the American Board of Internal Medicine (Gastroenterology,) a fellow of the Royal College of Physicians and Surgeons of Canada and a member of the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program.   Connect with Erin Judge, RD:  IG: https://www.instagram.com/erinjudge.rd TikTok: https://www.tiktok.com/@erinjudge.rd   Work with Gutivate:  https://gutivate.com/services   

What if a free, side-effect-free therapy could significantly improve your cancer survival— and even help prevent recurrence? In this episode, we explore the powerful, research-backed role of exercise in cancer prevention and treatment, centered around the recent CHALLENGE trial published in The New England Journal of Medicine. Here is the link to that study: https://www.nejm.org/doi/10.1056/NEJMoa2502760 Dr. Hassell shares groundbreaking findings showing that moderate, consistent exercise significantly reduces cancer recurrence and mortality — particularly in colon cancer survivors — when added to conventional treatments. More than just prevention, movement is positioned as a critical treatment tool that enhances immunity, reduces inflammation, balances hormones, and even boosts mental health. Key Takeaways: Exercise led to a 37% lower risk of death in colon cancer patients (CHALLENGE trial). Benefits appear as early as 1 year into a structured program (as little as brisk walking!). Sedentary lifestyles are now considered nearly as dangerous as smoking. Even 1-minute workouts a few times a day can start improving immune function. The “number needed to treat” for exercise is dramatically better than many standard medical therapies. Physical activity also reduces risk of diabetes, heart disease, depression, frailty, and more. Social, playful exercise (like frisbee or ping pong) boosts both body and mind — and reduces loneliness. Watch now to discover how just a few minutes of movement a day could change — or even save — your life. #CancerTreatment #ExerciseAndCancer #PreventativeHealth #ChallengeTrial #LifestyleMedicine #WalkDontRunPodcast #MentalHealth #ChronicDiseasePrevention More references can be found at www.GreatMed.org Would you like Dr. Hassell to answer your question on the air?  Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter.  We love to hear from you.  This podcast is sponsored by our generous listeners.  Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

There have been countless advances in controller therapies for asthma, but our go-to rescue inhaler, a quick-relief bronchodilator, hasn't changed in decades. In this episode of The Itch Review, we spotlight “As-Needed Albuterol–Budesonide in Mild Asthma” published in The New England Journal of Medicine, May 19, 2025. This article looks at the BATURA trial, which tested whether adding budesonide to albuterol rescue inhalers cuts exacerbations in adults whose mild asthma remains uncontrolled on occasional albuterol/short-acting beta agonist (SABA) therapy. Could this combo inhaler really cut severe asthma attacks in people with mild disease? What we cover in our episode about the BATURA trial: Understanding asthma: In asthma, your airways both tighten up and get swollen. Treating both the tightness and the swelling right when you feel symptoms could stop a full-blown attack. All-online trial: BATURA used telehealth to enroll 2,516 people with mild asthma from across the U.S. and ran the study until it saw a preset number of 172 serious attacks. Big takeaways: The combo inhaler cut serious attacks by almost half, halved yearly flare-ups, and slashed steroid use by 63%. All without people needing to use their medication more often. Why it ended early: An independent safety board reviewed the data mid-trial and concluded that the combo inhaler was so clearly better that it would've been unfair to continue giving anyone the old treatment. What's next: We still need studies on teens and children to ensure that these same benefits hold true for younger patients. GET THE INFOGRAPHIC PDF HERE *** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores the latest allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *** This podcast is made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Keine Zeit für gesunde Ernährung? In dieser Folge erfährst Du, wie Du trotz vollem Kalender schlanker, stärker und entspannter wirst – mit einem flexiblen Ernährungssystem, das Dir Zeit schenkt, statt nimmt.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Tipps für Tools:Yazio Pro* (Angebot für Hörer)Topf, Glasbehälter, Shaker und andere Tools (meine Empfehlungen)_____

The CHALLENGE trial at ASCO 2025 showed that increased physical activity improves survival rates in colon cancer patients, with the exercise group demonstrating better health outcomes and survival rates compared to those receiving only health education. A phase 3 trial in The New England Journal of Medicine found that semaglutide significantly improves liver conditions in MASH patients, showing better resolution of steatohepatitis and fibrosis improvement compared to placebo. Additionally, a study in the NEJM revealed that combining finerenone and empagliflozin offers enhanced kidney protection in patients with chronic kidney disease and type 2 diabetes, significantly reducing urinary albumin levels.

Le tabac est l'une des premières causes de mortalité évitable dans le monde. Chaque année, il est responsable de plus de 75 000 décès en France, et environ 8 millions dans le monde. Mais concrètement, combien d'années de vie le tabagisme fait-il perdre à ceux qui fument régulièrement ? La réponse, confirmée par de nombreuses études, est saisissante : en moyenne, un fumeur régulier perd entre 10 et 15 ans d'espérance de vie par rapport à un non-fumeur.Cette estimation ne repose pas sur une intuition, mais sur des données solides issues d'études épidémiologiques de grande ampleur. L'une des plus citées est celle menée par le British Doctors Study, une recherche de long terme commencée en 1951 sur plus de 34 000 médecins britanniques. Elle a montré que ceux qui fumaient régulièrement mouraient en moyenne 10 ans plus tôt que leurs collègues non-fumeurs. Ces résultats ont ensuite été confirmés par d'autres recherches, notamment une étude publiée en 2013 dans le New England Journal of Medicine, qui montrait que les fumeurs chroniques (ceux qui commencent à fumer avant 20 ans et poursuivent au long de leur vie) perdaient jusqu'à 13 années de vie.Pourquoi une telle perte ? Parce que le tabac est un facteur de risque majeur dans de nombreuses pathologies chroniques. Il est impliqué dans plus de 80 % des cancers du poumon, mais aussi dans de nombreux autres cancers (bouche, œsophage, pancréas, vessie). Il favorise également les maladies cardiovasculaires (infarctus, AVC), les bronchopneumopathies chroniques obstructives (BPCO), et une multitude d'autres affections respiratoires et inflammatoires.Mais il y a aussi une bonne nouvelle : arrêter de fumer, même tardivement, peut prolonger considérablement l'espérance de vie. Toujours selon les données du New England Journal of Medicine, un fumeur qui arrête avant l'âge de 40 ans récupère en moyenne 9 des 10 années perdues, et ceux qui arrêtent à 50 ou 60 ans gagnent également plusieurs années par rapport à ceux qui continuent.Le message est donc clair : le tabac tue, mais l'arrêt peut inverser une partie des dégâts, même après plusieurs années de dépendance. En résumé, un fumeur régulier peut s'attendre à vivre 10 à 15 ans de moins qu'un non-fumeur, mais il n'est jamais trop tard pour arrêter et gagner en espérance de vie… et en qualité de vie. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Send us a textA critique of SSRIs and pharma's influence on medicine, including SSRI-induced sexual dysfunction, suicidality, and violence. Long Summary: Dr. David Healy critiques modern medicine, focusing on SSRIs and psychiatric medicine, including: how pharmaceutical companies manipulate clinical trial data, ghostwrite studies, and influence medical practice, often ignoring patient experiences; highlighting issues like post-SSRI sexual dysfunction (PSSD), the immediate sensory effects of SSRIs, and their potential to induce suicidal or violent behavior; challenging the reliance on randomized controlled trials (RCTs) over individual patient reports; and more.About the guest: David Healy, MD, PhD, a psychiatrist and pharmacologist, has decades of experience researching the serotonin system and SSRIs, working across Ireland, the UK, Canada, and the US. He is a professor at McMaster University and a vocal critic of pharmaceutical industry practices.Discussion Points:SSRIs cause near-immediate sensory effects, like genital numbing, in most people.Post-SSRI sexual dysfunction (PSSD) can persist for years or decades after stopping the drug, affecting many long-term users.Healy argues RCTs prioritize averages over individual experiences, often missing serious side effects like suicidality.Pharmaceutical companies ghostwrite studies and manipulate data, with journals like the New England Journal of Medicine publishing misleading articles.Serotonin theory of depression lacks evidence.Industry tactics include dismissing patient reports as anecdotes and using high doses in trials to mask weak efficacy.SSRIs can increase suicide risk, not just during initiation but also when adjusting doses or withdrawing, as seen in cases like the Aurora movie theater shooting.Regulatory bodies like the FDA often fail to investigate adverse effects due to bureaucratic processes and lack of follow-up.Healy emphasizes doctors' failure to prioritize patient observations, driven by industry-influenced standards of care.Related episode:M&M 88: Depression, Serotonin, SSRIs, Psychiatry & Social Media | Joanna Moncrieff*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

About the Guest(s): Dr. Chad Woolner is a skilled healthcare professional specializing in chiropractic care and low-level laser therapy. With a deep understanding of chronic diseases and their connection to inflammation, Dr. Woolner has dedicated his career to exploring innovative treatment methodologies that enhance patient care. Focused on practical, non-invasive solutions, he is a co-host of "The Laser Light Show," where he passionately discusses laser therapies' benefits. Dr. Andrew Wells is a seasoned expert in chiropractic health and wellness. With a focus on holistic healthcare approaches, Dr. Wells has extensive experience in managing chronic diseases and inflammation. His expertise spans various integrative health strategies, making him a valuable resource for innovative treatment modalities, including the usage of lasers for immune and musculoskeletal health improvement. Episode Summary: In this enlightening episode of "The Laser Light Show," Dr. Chad Woolner and Dr. Andrew Wells delve into the pervasive issue of inflammation and uncover how low-level laser therapy provides a promising solution. Drawing connections between inflammation and chronic diseases, such as arthritis, heart disease, and depression, they propose an unconventional method not to be ingested but rather utilized through light. The discussion promises to embrace health practitioners and patients alike, offering newfound insights into this therapeutic technique. This episode explores the complex nature of inflammation, emphasizing its dual role as both a healing and harmful force. Dr. Woolner and Dr. Wells discuss how traditional medicinal approaches, such as NSAIDs, often fall short with their adverse side effects, shifting the focus toward laser light therapy as a safe, effective alternative for reducing inflammation. Through highlighting the positive impact on mitochondrial stimulation and oxidative stress reduction, the hosts lay out a compelling case for lasers as a non-invasive method to not only manage inflammation but potentially revolutionize chronic disease treatment. Key Takeaways: Low-level laser therapy offers a powerful, non-invasive tool for addressing inflammation associated with chronic diseases. Chronic inflammation can result from various stimuli and lead to serious health conditions. Laser therapy can modulate inflammation by boosting mitochondrial activity, reducing oxidative stress, and influencing cellular signaling. Safe and effective, Class 2 lasers, such as those from Erchonia, offer significant health benefits without the harmful side effects associated with high-powered lasers or medications. Utilizing lasers, patients can experience increased energy, aiding healthier lifestyle transitions. Notable Quotes: "Every chronic disease, from arthritis to heart disease to depression, has one thing in common, and that is inflammation." - Dr. Chad Woolner "It's equipping your body to be able to manage the insult that's happening, but to reduce the damaging effects." - Dr. Andrew Wells "NSAIDs might help pain today, but they also may be slowly tearing apart your gut lining tomorrow." - Reference from the New England Journal of Medicine "That's the interesting thing, that's what makes it so safe, right. Is it's the body takes in that wavelength and then the body knows what to do with that energy to get back into homeostasis." - Dr. Andrew Wells "Lasers can be used immediately. It doesn't require the same degree of discipline that changing diet oftentimes can for patients." - Dr. Chad Woolner Resources: Follow Dr. Andrew Wells on LinkedIn for insights into holistic chiropractic approaches. Explore more from Dr. Chad Woolner on The Laser Light Show podcast for discussions on low-level laser therapies. Tune in to this episode to discover how laser therapy might just be the innovative, holistic approach necessary to combat inflammation and chronic diseases. Stay connected for more transformative content in the healthcare field from the Laser Light Show!

Send us a textIn this episode, Marla Dalton, PE, CAE, and William Schaffner, MD, talk with Craig Spencer, MD, MPH, emergency physician and global health expert, about what it takes to lead in times of crisis. From treating Ebola patients in Guinea to navigating COVID-19 in New York, he reflects on the power of empathy, the importance of cultural understanding, and the fight for health equity. He also shares the personal sacrifices behind public service—and why the lessons of past pandemics must not be forgotten.Show notesAssociate professor at Brown University School of Public Health, Spencer has nearly 2 decades of experience in global health and humanitarian response, having worked on critical public health issues across Africa, Southeast Asia, and beyond, including leading epidemiological responses during the West African Ebola outbreak. His work focuses on the historical foundations of public health, humanitarian response, and pandemic preparedness. His writing has appeared in The New York Times, The Atlantic, The New England Journal of Medicine, The Washington Post and more. He is a life member of the Council on Foreign Relations and serves on the Board of Advisors for Doctors Without Borders USA.Follow NFID on social media

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright answer listener questions from around the world about metabolic health. This mailbag episode explores widely-debated topics like “starvation mode,” weight loss plateaus, the relationship between metabolism and cognitive health, cannabis and metabolism, metabolic effects of liposuction, and the latest on GLP-1 medications.Key Takeaways:Dr. Cooper dispels myths around “starvation mode,” citing research on the long-term metabolic impact of dieting and caloric restriction.Weight loss plateaus are often misunderstood—Dr. Cooper explains the natural adaptations behind them and how to assess true progress.Metabolic health plays a major role in brain function, cognitive decline, depression, and dementia prevention.Cannabis affects metabolic pathways in complex ways, with regular use potentially causing negative metabolic effects.Liposuction can trigger metabolic rebound and rapid fat regain for some patients, especially when leptin levels are low.Updates on GLP-1 meds: Liraglutide is available in generic form, but costs fluctuate. New oral and combination therapies are on the horizon.Personal Stories & Practical Advice:Andrea and Mark reflect on their own journeys with dieting, weight plateaus, and medication.Dr. Cooper shares clinical experiences with metabolic rebound after liposuction and ways to navigate pharmacologic treatments.Correction: Lilly has a lower cash pay for Medicare and Medicaid, but Novo Nordisk is not yet.References related to diet-induced metabolic adaptation, also called biological adaptation and defense of body weight. 1. Keys, A., Brozek, J., Henschel, A., Mickelsen, O., & Taylor, H. L. (1950). The Biology of Human Starvation. University of Minnesota Press.2. Dulloo, A. G. (2021). Physiology of weight regain: Lessons from the classic Minnesota Starvation Experiment on human body composition regulation. Obesity Reviews, 22, e13189.3. Müller, M. J., & Bosy-Westphal, A. (2013). Adaptive thermogenesis with weight loss in humans. Obesity, 21(2), 218-228.4. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(S1), S47-S55.5. Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., ... & Hall, K. D. (2016). Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 24(8), 1612-1619.6. Johanssen, D. L., Knuth, N. D., Huizenga, R., Rood, J., Ravussin, E., & Hall, K. D. (2012). Metabolic slowing with massive weight loss despite preservation of fat-free mass. Journal of Clinical Endocrinology & Metabolism, 97(7), 2489-2496.7. Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 365(17), 1597-1604.8. MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2011). Biology's response to dieting: the impetus for weight regain. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 301(3), R581-R600Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Whose lab created SARS-CoV-2? Virologist Dr. Li-Meng Yan says it was “all China.” But Dr. Clayton Baker insists US biolabs at UNC Chapel Hill played a role. A new Brownstone report points at “US virologist Ralph Baric” and alleges damning details that indicate he “engineered the Covid-19 virus SARS-CoV-2 in his lab at the University of North Carolina as part of his work in connection with the 2018 DEFUSE funding proposal” first leaked by “Major Joseph Murphy, an employee of US military research agency DARPA, in the summer of 2021…” Dr. Li-Meng Yan is a Chinese virologist with an MD from Central South University and PhD in ophthalmology from Southern Medical University. She hosts The Voice of Dr. Yan on America Out Loud Radio Network and is best known for publishing claims that SARS-CoV-2 originated in a Chinese lab. More at https://x.com/DrLiMengYAN1 Dr. Clayton Baker, an internal medicine physician, has over 25 years in clinical practice. He served as Clinical Associate Professor at the University of Rochester from 2012 to 2018. His work appears in the Journal of the American Medical Association and the New England Journal of Medicine. He authored The Medical Masquerade and contributes to Brownstone Institute. More at https://x.com/cjbakermd 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠⁠⁠⁠https://drdrew.com/skinrepair⁠⁠⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - New England Journal of Medicine 2025. Discussion by:Guest: Steven E. Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland ClinicProfessor of Medicine at the Lerner College of Medicine2. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025).Discussion by: Discussion by:Guest:Anupriya Grover-Wenk, DO Faculty– Family Medicine Residency ProgramJefferson Health – Abington3. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Discussion by:Guest: Joseph Gonnella, MDResident– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

We've been talking about RFK Jr for years, and even dedicated an entire chapter to him in our 2023 book—and we're going to keep covering him. Since his power and influence has only grown, and since he's now in charge of America's entire health apparatus, there's no way to avoid it. This week we catch up on the last few months of MAHA. Derek looks into why he believes Kennedy's apparatus, despite claims of being about health, is really a cover for Project 2025's deregulatory agenda. Julian discusses a recent paper published in the New England Journal of Medicine by Covid contrarians Marty Makary and Vinay Prasad, who now both work under Kennedy. Finally, Matthew will contemplate Kennedy's crude remarks on autism through the lens of disability politics. Show Notes What Has All This Restaurant Food Done to My Gut? Function Health is Another Theranosesque Scam MAHA's Goal Is Not Health: Robert Kennedy's movement promises more privatization RFK Jr. meets with health tech startups, most backed by Andreessen Horowitz COVID infection no longer gives lasting immunity Hybrid Immunity May Be the Key to Developing Better Vaccines Makary, Bhattacharya in New England Journal of Medicine Consequences of Work Requirements in Arkansas: Two-Year Impacts on Coverage, Employment, and Affordability of Care  Concerns About ABA-Based Intervention: An Evaluation and Recommendations - PMC  Adler-Bolton, Beatrice, and Artie Vierkant. 2022. Health Communism: A Surplus Manifesto. Verso Books. SURPLUS. Adler-Bolton, The New Inquiry. October 18, 2022.  Extractive Abandonment - Stimpunks Foundation  Social and medical models of disability and mental health: evolution and renewal - PMC Learn more about your ad choices. Visit megaphone.fm/adchoices

Join our Patreon and get access to monthly bonus episodes and more nutriton content!Can fasting really slow aging? Does calorie restriction work for humans, or just for mice and yeast? And how much protein do you actually need to age well? This week on Your Diet Sucks, we break down the evidence behind the most talked-about interventions in the longevity space, what holds up under scrutiny, what doesn't, and why you might not need a supplement stack to live longer, and enjoy life. We dig into:The actual science on calorie restriction, fasting, and supplements—and where the evidence stopsWhat inflammation, oxidative stress, and telomeres have to do with how we ageThe best-researched dietary patterns for living longer (hint: it's not sexy, but it might include red wine)Why protein becomes more important as we ageThe difference between lifespan and healthspan, and why quality of life needs to be part of the conversation

Join the University of Washington Surgical Palliative Care Team for their final episode of this series — a dual journal review and clinical challenges discussion on assessing medical decision-making capacity. Using Dr. Paul Applebaum's foundational framework, the team outlines the four key criteria for evaluating capacity and brings the topic to life through two contrasting standardized patient scenarios. This episode highlights why capacity assessment is not only relevant but essential for surgeons navigating complex, high-stakes decisions.  Hosts:  Dr. Katie O'Connell (@katmo15) is an associate professor of surgery at the University of Washington. She is a trauma surgeon, palliative care physician, director of surgical palliative care, and founder of the Advance Care Planning for Surgery clinic at Harborview Medical Center, Seattle, WA. Dr. Ali Haruta is an assistant professor of surgery at the University of Washington. She is a trauma and emergency general surgeon and palliative care physician. Ali recently completed fellowships in palliative care at the University of Washington and Trauma and Critical Care at Parkland.  Dr. Lindsay Dickerson (@lindsdickerson1) is a PGY6 general surgery resident at the University of Washington with an interest in surgical oncology.   Dr. Virginia Wang is a PGY3 general surgery resident at the University of Washington. Learning Objectives: 1.        Decipher the distinction between the terms “capacity” and “competence”.   2.        Describe the four criteria for assessing medical decision-making capacity presented in Dr. Paul Applebaum's article “Assessment of Patients' Competence to Consent to Treatment.” 3.        Apply the capacity assessment framework to real-world clinical scenarios in surgical practice.  References: 1.        Applebaum, PS. Assessment of Patients' Competence to Consent to Treatment. New England Journal of Medicine 2007; 357(18):1834-1840. https://pubmed.ncbi.nlm.nih.gov/17978292/ 2.        Special thank you to Mr. Mark Fox for his acting contribution to this episode. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Can joint Israeli-Palestinian health programs help build trust where politics have failed? According to a new paper published in the New England Journal of Medicine, the health care field can play a crucial role in building bridges between communities in conflict. Written by two Jewish Israeli and two Palestinian doctors during a period of temporary ceasefire between Israel and Hamas, the paper reviews 16 joint initiatives, highlighting in particular two programs: Road to Recovery and Physicians for Human Rights Israel. The authors also present recommendations on how cross-national health care programs can play a role in post-war peacebuilding. One of the paper's authors, Avner Halperin, a senior fellow at the Harvard Kennedy School's Middle East Initiative, spoke to KAN reporter Naomi Segal. (Photo: Billie Weiss)See omnystudio.com/listener for privacy information.

Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after inking a clinical trials collab for a similar drug with Summit Therapeutics. It's the largest Chinese licensing deal in recent memory, as pharmas continue to turn to the country to fill their pipelines.  Also on Tuesday, the Department of Health and Human Services offered a smidge more detail on President Donald Trump's Most Favored Nation executive order. A press release explained that drug prices will be tied to the lowest price in certain countries with a GDP at least 60% that of the U.S. and that the effort will focus on branded drugs.   Over at the FDA, the strategy around COVID-19 vaccines is evolving. According to an editorial published in the New England Journal of Medicine Tuesday by FDA Commissioner Marty Makary and CBER director Vinay Prasad, future COVID-19 approvals will focus on adults over 65 and high-risk individuals six months to 64 years old—a strategy they say will better align the U.S. with other high-income nations. This is also in sync with the Novavax approval, which came in Friday after a few delays.   Meanwhile, the FDA's Oncologic Drugs Advisory Committee (ODAC) is currently in the midst of a two-day meeting, but acquiring the necessary expertise was “absolute chaos,” according to an agency insider who spoke with BioSpace. This is partly due to the decimation of an FDA office that includes staff responsible for screening scientific and therapeutic area experts for conflicts of interest.  Going back to last week—which seems like a year ago at this point—we were somewhat shocked to learn that the CEO of one of the world's most valuable pharma companies is on his way out. Friday morning, Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will be leaving the company after eight years at the helm. After peaking last June at about $155 apiece, the obesity leader's shares are currently worth just $68. Novo said the decision for Jorgensen to leave was mutual, but Jorgensen was not made available to speak on a call following the announcement.  Finally, a couple of milestones are worth noting: First, the Alzheimer's space got a big win on Friday when the FDA approved the first blood-based test for the disease—news that could be a boon to Eli Lilly's Kisunla and Biogen & Eisai's Leqembi. And second, a nine-month-old boy named KJ with a disease called CPS1 deficiency that affects just 1 in 1.3 million U.S. babies was treated with a single-use CRISPR treatment created just for him. It's an incredible story that highlights just how far gene editing has come, but it also highlights a rare disease crisis, with these sorts of ultra- and nanorare diseases lacking the necessary financial incentive to motivate biopharma's focus.   

How do we make artificial intelligence more intelligent? This week, Technology Now dives deep into the world of AI agents and how they interact with large language models. We ask what are some of the current problems with AI, and examine how applying agents can help artificial intelligence to provide better answers to our questions. Jimmy Whitaker, Chief Scientist in the AI Private Cloud Group at HPE, tells us more.This is Technology Now, a weekly show from Hewlett Packard Enterprise. Every week, hosts Michael Bird and Aubrey Lovell look at a story that's been making headlines, take a look at the technology behind it, and explain why it matters to organizations and what can be learnt from it.Jimmy Whitaker: https://www.linkedin.com/in/jimmymwhitaker/Sources cited in this week's episode:Today I learned: https://www.simonsfoundation.org/2025/04/29/flares-from-magnetized-stars-can-forge-planets-worth-of-gold-other-heavy-elements/Anirudh Patel et al., 2025, Direct Evidence for r-process Nucleosynthesis in Delayed MeV Emission from the SGR 1806–20 Magnetar Giant Flare, ApJL 984 L29, DOI 10.3847/2041-8213/adc9b0This week in history:Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982 May;10(2):53-9. doi: 10.1016/0196-6553(82)90003-7. PMID: 7044193.Muyembe JJ, et al, 2024, Ebola Outbreak Response in the DRC with r-VSV-ZEBOV-GP Ring Vaccination, The New England Journal of Medicine, 2024;391:2327-2336, VOL. 391 NO.24, https://www.nejm.org/doi/10.1056/NEJMoa1904387https://www.who.int/health-topics/poliomyelitis#tab=tab_1

Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO   Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1.  Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds!   Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami.  What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Our guest's disclosures will be linked in the transcript.  David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging.  Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself.  Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it.  And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology.  The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction.  And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts.  David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.

CBS News MoneyWatch correspondent Kelly O'Grady breaks down what to know about the potential financial impact to American consumers after the U.S. and China agreed to temporarily ease tariffs. Music superstar Taylor Swift has been subpoenaed in the ongoing legal dispute between Blake Lively and Justin Baldoni over allegations surrounding the making of their 2024 film "It Ends with Us."  A new study from the New England Journal of Medicine compares two weight loss drugs, Tirzepatide and Semaglutide. CBS News medical contributor Dr. Celine Gounder breaks down the findings. Nicole Scherzinger is making her Broadway debut in the stripped down, modern revival of "Sunset Blvd." She talks with "CBS Mornings" about the show, taking on the role and her first Tony nomination. In an exclusive "Begnaud's America" interview, CBS News contributor David Begnaud speaks with Gus Waltz, the son of Minnesota Gov. Tim Walz, who stole the spotlight during the 2024 Democratic National Convention. He's opening up about that moment and a learning disorder that is often misunderstood. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Dr. Florence Comite, MD is a clinician-scientist, endocrinologist, and the leading expert in the fields of healthy longevity and precision medicine. Her international reputation stems from her innovative approach to leveraging proprietary clinical and wearable data in her private clinical and virtual practice to detect, predict, and reverse biological aging, while optimizing health and vitality.   As a graduate of Yale School of Medicine, Dr. Comite served as a faculty member for twenty-five years with a distinguished triple appointment in Endocrinology (Internal Medicine and Pediatrics) and Reproductive Endocrinology (Gynecology and Andrology). During her career, she trained at the National Institutes of Health and founded Women's Health at Yale, establishing the nation's first women-only clinic.   In 2005, Dr. Comite founded the Comite Center for Precision Medicine & Healthy Longevity in New York City, where she developed the groundbreaking Nof1™ clinical process, treating each patient as a single subject clinical trial. The Center's success has led to expansions in Palo Alto and Miami Beach. Her innovative approach has attracted a global clientele, including forward-thinking physicians, industry leaders, and entrepreneurs, each receiving personalized healthcare interventions tailored to their individual needs. Her commitment to advancing medical science is evident through her extensive research and publications in prestigious journals such as the New England Journal of Medicine, JAMA: The Journal of the American Medical Association, and the Journal of the Endocrine Society. Dr. Comite's pioneering research spans across children, women, and men, recognizing the critical role of the entire system in aging and disease.   In 2013, she authored the bestselling book "Keep It Up: The Power of Precision Medicine to Conquer Low T and Revitalize Your Life," focusing on androgen deficiency and vitality in aging men. Her next book, "Invincible: Eliminate the Disorders of Aging for a Healthy, Long Life," will be published by Little Brown, Spark in Spring 2026. Through her startup Groq Health, Dr. Comite is scaling her precise methodology of precision medicine to a digital clinic delivered virtually.   As a sought-after keynote speaker, Dr. Comite continues to captivate audiences worldwide, sharing her expertise and vision for the future of precision medicine and healthy longevity.

The DOJ is investigating top medical journals for biased editorial practices, alleging they suppressed studies on COVID-19 vaccine risks and alternative therapeutics for partisan reasons. NBC reports the science publications (including CHEST, New England Journal of Medicine, and Obstetrics and Gynecology) were sent letters “questioning their editorial practices.” In response, medical journal The Lancet called the letters “harassment” and claimed science in the USA was being “violently dismembered” by all of these annoying questions being asked by the peasants. “This corrupt web of suppression, fraud, and retractions demands a legal reckoning,” writes epidemiologist Nicolas Hulscher. Dr. Ram Yogendra, MD, MHP, is a board-certified anesthesiologist with a public health background. He advocates for vaccine injury research, highlighting issues like the persistence of S1 spike protein in monocytes post-COVID-19 vaccination. More at https://x.com/dryostradamus and https://covidlonghaulers.com Elijah Schaffer is a journalist for The Gateway Pundit and the host of Slightly Offensive on Censored.TV. He's also a news presenter on Vigilant News Network. Schaffer filmed the Kyle Rittenhouse shootings, was inside the Capitol on January 6, 2021, and went undercover in groups like Antifa and BLM during the 2020 riots. More at https://x.com/ElijahSchaffer 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠https://drdrew.com/sponsors⁠⁠  ⁠⁠⁠ • FRESH PRESSED OLIVE OIL – Olive oil packs the most flavor and healthiest nutrients when it's fresh. Don't settle for stale supermarket olive oils – get it direct from small, award-winning farms! Get your free $39 bottle for just $1 shipping & taste the difference at ⁠https://GetFreshDrDrew.com/ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠https://drdrew.com/skinrepair⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠https://drdrew.com/fatty15⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠https://drdrew.com/paleovalley⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠https://twc.health/drew⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠https://kalebnation.com⁠⁠) and Susan Pinsky (⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠e⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Healthcare Plus Podcast, Quint Studer is joined by Dr. Roger Kapoor, physician leader and author of Working Happy!: How to Survive Burnout and Find Your Work/Life Synergy in the Healthcare Industry. Quint and Dr. Kapoor dive deep into one of healthcare's most urgent challenges: burnout. Drawing from personal experience, clinical insight, and extensive research, Dr. Kapoor explores why so many healthcare professionals are feeling overwhelmed—and what we can do about it. He explains that burnout isn't just a workplace issue; it often starts within ourselves, and recognizing this can be the first step toward healing.Listeners will hear why “work/life balance” may be a flawed concept and how “work/life synergy” can offer a more sustainable, fulfilling way forward. They'll learn about the powerful concept of ikigai (a Japanese term for “reason for being”) and how finding purpose in even the smallest moments can bring resilience and joy back to a healthcare career. Dr. Kapoor also explores fundamentals like diet, exercise, and sleep in a way that's fresh and compelling. (You'll love his insights on the “night shift janitors” that clear out the waste in our brains.)This episode is a must-listen for anyone in healthcare who's grappling with stress, seeking practical ways to recharge, or simply wanting to reconnect with the meaning behind their work.About Dr. Roger KapoorRoger Kapoor, MD, MBA, is the senior vice president of Beloit Health System in Beloit, Wisconsin, a community-based nonprofit hospital with approximately 23 service locations. He is a Harvard-trained dermatologist who also holds an MBA from the University of Oxford in England and has authored numerous peer-reviewed scientific articles published in professional journals including the New England Journal of Medicine. He was the recipient of the Wisconsin Medical Society's Kenneth M. Viste, Jr., MD, Young Physician Leadership Award and named one of the Top 25 Emerging Leaders in Healthcare by Modern Healthcare.  Kapoor has been credited with re-engineering the delivery of healthcare to his community, resulting in a dramatic rise in patient satisfaction at his institution from a stagnant 16th percentile to an astonishing 88th percentile in less than a year. He concurrently ushered in transformative results in quality, leading teams to achieve three consecutive “A” ratings from the national watchdog group Leapfrog, a four-star rating from the Centers for Medicare & Medicaid Services Five-Star Quality Rating System, and numerous quality-of-care pathway accolades. As a practicing board-certified dermatologist, he has built a successful medical and cosmetic dermatology practice using advanced techniques to help patients live happier, healthier lives. His book Working Happy! How to Survive Burnout and Find Your Work/Life Synergy in the Healthcare Industry was published in 2024.

In this episode of THE MENTORS RADIO, host Tom Loarie talks with Justin Stebbing, M.D., a London-based, world-renown scientist, cancer researcher, medical journal editor and author. Dr. Stebbing talks about the excitement and rewards of a STEM career, the life of a scientist, and about his own journey to becoming a world-renown clinician and scientist. He also about the tremendous wonder of discovering improved therapies for cancer and for treating covid. Professor Justin Stebbing, M.D., is also a professor of biomedical sciences at ARU, Cambridge, and a visiting professor at Imperial College where he has an active and widely known translational laboratory. He is the author of more than 700 peer-reviewed papers published in The Lancet, The New England Journal of Medicine and elsewhere. Dr. Stebbing is the co-chief editor of Oncogene and author of the book, Witness to Covid. Find Show Notes below. Listen to this episode below and on ANY podcast platform (from Apple to Spotify, Google, Stitcher, Spotify, TuneIn, etc) by typing in “THE MENTORS RADIO” … even easier, Subscribe HERE to listen on any podcast platform!!! SHOW NOTES: JUSTIN STEBBING, M.D.: BIO: https://www.imperial.ac.uk/people/j.stebbing AND https://justinstebbing.me/ BOOK: Witness to Covid: The diary of a global pandemic, by Professor Justin Stebbing ARTICLES: PROFESSOR JUSTIN STEBBING: The revolution that makes me believe we really CAN beat cancer in my lifetime

In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial's rationale, design, and real-world implications for patients with relapsed or refractory disease. Tune in to hear expert perspectives on unmet needs in late-line myeloma care, emerging toxicity profiles, and the future of dual-targeted immunotherapy.

Send us a textI am truly excited about this new segment brought to ya' by Ochsner's Childrens' Hospital! Milk-Bank Miracles with Dr. Harley Ginsberg will shine light on what the NICU is and what hospitals do to keep our little, itty bitty nuggets alive! It really is miraculous.  Dr. Ginsberg is the founder and medical director of Mothers' Milk Bank of Louisiana at Ochsner Baptist. He has written chapters for medical textbooks on neonatology and has published scientific medical articles in the New England Journal of Medicine, the Journal of Perinatology, and Clinics in Perinatology among others. Dr. Ginsberg's professional interests include the use of donor human milk to prevent neonatal intestinal disease as well as the role of human milk in infection prevention.  I am blown away by this opportunity to partner with him and open a window for our audience to learn more not only about his Mother's Milk-Bank but also the guided hand to learn about the NICU! (Neonatal Intensive Care Unit.)To learn more about this go to: www.ochsner.org_______________________________________________________________________________________________Then later we welcome New Orleans Council Member Lesli Harris to hear about what our city is doing to combat our homeless crisis. I met Council Member Harris one hot and blazey summer afternoon and since then, she has graced our show with her smile and passion for our city. I was so inspired by her devotion in this area of SO MANY areas to focus on. I learned by our interview that over 200 individuals have been rehabilitated through the "Home For Good Program" (https://homeforgoodneworleans.org)                                        Over 1,000 individuals have been taken off the street and ARE GIVEN recourses in all aspects of life; not to only get them off the streets, but to give them dignity, confidence and motivation to get back up and make the next day better than the last. I wish you could see Council Member Lesli Harris' eyes when she presents the raw data, stats and numbers that really are jolting. There were a couple of topics that we didn't see quite eye to eye, but that is what civil dialogue is and unfortunately has been lost in our country for some time now.  I came to her with urgency because of a situation that happened with me and my family in the Marigny a couple of months back. It startled me, and I felt helpless. I don't like that feeling, ESPECIALLY when my babies are with me.  My fear is that if the homeless numbers don't fall, the Governor will come in without warning and sweep the city before the city council, mayor, police chief etc. can do one thing. I am encouraged by the newly released nola.com article that showed Council Member Lesli's vision. IS WORKING. And that bottom line is all I truly worry about. Her candor, smile and authenticity won me over from the beginning and I am still living for it. THANK YOU COUNCIL MEMBER HARRIS! Read the article I spoke about here,  Lesli Harris: New Orleans' homeless efforts are workingThank you to our family of amazing sponsors! Ochsner Hospital for ChildrenWww.ochsner.orgRouses MarkersWww.rousesmarkets.comSandpiper VacationsWww..sandpipervacations.comCafe Du Monde www.shop.cafedumonde.com The Law Firm of Forrest Cressy & James Www.forrestcressyjames.comComfort Cases Www.comfortcases.orgNew Orleans Ice Cream CompanyWww.neworleansicecream.comERA TOP REALTY: Pamela BreauxAudubon Institute www.auduboninstitute.orgUrban South Brewery www.urbansouthbrewery.com

CBS News has obtained an exclusive video of a man with alleged ties to North Korean leader Kim Jong Un's regime during what he thought was an interview for a job at an American tech company. CBS News' Nicole Sganga has more. A study from the New England Journal of Medicine found new evidence that GLP-1 drugs used for diabetes and obesity could also help people with a type of liver disease. CBS News contributor Dr. Celine Gounder explains the findings. A Nashville mom and former TV meteorologist says she's the victim of an online sextortion scam. Bree Smith spoke to "CBS Mornings" about how she's fighting back after her image was doctored into explicit pictures and videos for money. It's a scam the FBI says targeted tens of thousands of Americans last year. CBS News correspondent Kris Van Cleave shares which vehicles top the list for teen driver safety, including several budget-friendly options.Wilmer Valderrama talks with "CBS Mornings" about the upcoming "NCIS" finale, his nine seasons on the hit series, and why the show continues to draw millions of viewers worldwide. In the latest "Never Too Late" feature, Nate Burleson pushes past fear once again—this time by diving into shark-infested waters to face his ocean phobia head-on.Tony winners Sarah Paulson and Wendell Pierce join "CBS Mornings" to announce this year's major nominees and share memories from their acclaimed stage performances. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In an April 23rd executive order (EO), the president of the United States alleges that the Liaison Committee for Medical Education (LCME) and the Accreditation Council for Graduate Medical Education (ACGME) are requiring medical schools and residency programs to pursue unlawful discrimination through DEI policies. The EO calls for the US Department of Education to “assess whether to suspend or terminate” them, and to “streamline the process” for recognizing new accreditors to replace them.  In addition, medical journals, including the New England Journal of Medicine, are getting letters from a US Attorney, calling them “partisans in various scientific debates,” and requesting information.  As a follow up to our last episode on authoritarianism and its implications for the medical profession, we consider these new developments from two perspectives: On the one hand we look for evidence to support the government's claims; and, on the other, we consider how they fit into the authoritarian's playbook of capitalizing on polarization to breakdown civil society and consolidate power.  There are things physicians and other health professionals can and should be doing now – and we propose a few -- to protect our profession from an authoritarian incursion that threatens our commitment so scientific integrity, and to a medical education system that, however imperfect, is informed by expert knowledge and professional values.

US healthcare costs and spending are extreme made evident by the fact healthcare at a $5 trillion annually accounts for roughly half the global healthcare market. This reality led Princeton's Nobel Prize Economist Angus Deaton to conclude in 2020, “the industry is a cancer at the heart of the economy.” Though healthcare costs are projected to rise 7 to 8%, this year, cost growth over the past 15 plus years plus has not on average exceeded GDP growth - made evident by the fact that while the 2020 Medicare Trustee report concluded the Medicare hospital trust fund would be bankrupt by 2026, the most recent report concluded 2036. Prof. Buntin's recent writing on the topic, “The Value Zeitgeist, Considering the Slowdown in Healthcare Spending Growth,” coauthored by Harvard's Ellen Meara and Dartmouth's Carrie Colla, was published in “The New England Journal of Medicine” on April 12th. Prof Buntin's recent publications are at: https://hbhi.jhu.edu/expert/melinda-buntin. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSteve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

In this episode of From First Period to Last Period, Katherine shares her emotional and unexpected story: a molar pregnancy that led to cancer treatment. It's a powerful reminder of how complex and unpredictable reproductive health can be — and why these conversations matter.Kristyn and Dr. Jenna Kahn also tackle some of your most Googled questions: BV vs. UTI — what's the real difference, and why does it matter? How heavy is too heavy when it comes to your period? And, what's the deal with intermittent fasting — helpful or hype? Our friend Anna Bohnengel, RDN, breaks this one down. Plus, we dive into a groundbreaking new study in The New England Journal of Medicine that's changing the way we think about BV: treating male partners too could reduce recurrence by over 50%. Could BV actually be sexually transmitted after all?Hit play now on Spotify, Apple Podcasts, YouTube, or wherever you listen!

The scientific method involves observation, questioning, forming hypotheses, testing predictions and altering theories to align with results; it is not the altering of results to align with a hypothesis.  There are three acceptable narratives about COVID-19: a wet mart (official), 5G (conspiracy), and laboratory leak (alternative). Whereas the https://www.science.org/content/article/cia-bribed-its-own-covid-19-origin-team-reject-lab-leak-theory-anonymous-whistleblower to reject the lab theory, https://apnews.com/article/covid-cia-trump-china-pandemic-lab-leak-9ab7e84c626fed68ca13c8d2e453dde1 explanation. This announcement was made just days after the former President regained the White House. As of April 2025, the https://www.whitehouse.gov/lab-leak-true-origins-of-covid-19/?fbclid=IwY2xjawJv5wdleHRuA2FlbQIxMAABHrhaCm1LYQx2UbG8uGLw5gkhCvB3N4a2gNrAgdarT7Z6C-XKZijSXHb3PctU_aem_hUJWc6XJ_Gfj14AvDa1VSA as “the true origins of COVID-19.”  This new official designation means that at one time or another two totally different explanations were given, ultimately with the consequence of censorship and ridicule if a person thought or said anything different. Both explanations still result in justufciaotn for past, and future, measures such as: social distancing, masking, https://www.theatlantic.com/ideas/archive/2021/04/end-hygiene-theater/618576/ as a form of a theater, vaccines, etc.  Prior to the recent shift in narratives, undercover video reportedly proved that Pfizer was indeed conducing gain of function research in a laboratory. But that lab was not a viral facility or a Wuhan institute; instead, it was a computer lab. In fact, https://www.pfizer.com/news/announcements/pfizer-responds-research-claims stating: “With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations…” Such computer simulations were used to predict mass casualties from COVID, too, and are the same ones being employed for Climate Change narratives. But what is COVID-19 or the virus designated SARS-COV-2. It is a list or complex of symptoms that are classified into categories of disease. Examination of COVID's symptoms prove they are nearly identical to the common cold and flu, among others. In fact, the https://hsph.harvard.edu/news/a-sharp-drop-in-flu-cases-during-covid-19-pandemic/. According to Harvard, this was the result of “wearing masks and distancing,” though they did not explain how such measures stopped the flu but not SARS-COV-2. Consider these three sets of symptoms from the CDC website: https://www.cdc.gov/common-cold/about/index.html: runny nose or nasal congestion, cough, sneezing, sore throat, headache, mild body aches, fever.https://www.cdc.gov/flu/signs-symptoms/index.html: runny or stuffy nose, cough, sore throat, headaches, muscle or body aches, fatigue, fever, and vomiting or diarrhea.  https://www.cdc.gov/covid/signs-symptoms/index.html: congestion or runny nose, cough, sore throat, headache, muscle or body aches, fatigue, fever or chills, nausea or vomiting, and diarrhea.  The only distinct symptoms of COVID were “shortness of breath or difficulty breathing” and “new loss of taste or smell.” The first symptom is already https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm in the United States - chronic lower respiratory disease. Since COVID was first tested CLRD has been bumped to sixth, though many of these respiratory deaths have been listed as COVID. In other words, what would have been diagnosed as CLRD was categorized instead as COVID-19. This is the same reason flu nearly disappeared as reported cases. These breathing problems were, within the COVID diagnosis, themselves sub-categorized as COVID-Pneumonia, and https://my.clevelandclinic.org/health/diseases/24002-covid-pneumonia.   The second symptom of losing a senes of taste or smell varied between total loss and partial loss, something that also occurs with the common cold and flu. This distinct and often promoted https://www.healthline.com/health-news/who-is-most-likely-to-lose-their-sense-of-smell-and-taste-from-covid-19, and even so only involved some often minor or unspecified form of loss.  Thus we can determine that between 15-37% of COVID cases had “distinct” symptoms arguably different than the overall symptoms that classify cold or flu, which means at liberal estimates over two thirds of COVID cases were nothing more than a case of the cold or flu. When defining what caused these other symptoms, we know recategorized pneumonia was one. But what about other causes that resulted in loss of senses?  Other than injuries or inflammation, often caused by what we call allergies, https://www.livestrong.com/article/13731552-food-suddenly-tastes-different/ and https://pubmed.ncbi.nlm.nih.gov/27178656/, as can neurological disorders. Other than the obvious and physical, there is also the psychological. Anxiety and stress are well known to alter sense perceptions, including https://www.calmclinic.com/anxiety/signs/smell and https://pmc.ncbi.nlm.nih.gov/articles/PMC10668578/. Consider how much anxiety and stress were cultivated by 24-hour coverage of cases, deaths, symptoms, videos from China, etc., and how wiling the public was to adopt any perceptually legal or even illogical dictate for the purposes of keeping themselves and others “safe.” There is a long history of such mass psychogenic pathogen.Much of this fear was generated by variant names like “KRAKEN,” a mythical monster, as was https://www.unmc.edu/healthsecurity/transmission/2023/09/19/meet-the-man-who-named-covids-new-variants/ who likewise believed this naming heightened the public's perception of a terror they should be feeling. Such fear became so intense that one analysis suggested that COVID activated “archetypes of evil” and thus “added psychological suffering.” The study suggested: “Fear and grief caused by the pandemic have produced a powerful unconscious narrative in the collective psyche that the coronavirus is driven by an https://pmc.ncbi.nlm.nih.gov/articles/PMC8441919/. The resulting archetypal dimension of fear causes an extra layer of psychological suffering in individuals.”  Such mythical, theological, and even magical terms were not lost in the New England Journal of Medicine which openly declared in 2020 that masks were little more than talismans: “Masks are not only tools, https://www.nejm.org/doi/full/10.1056/NEJMp2006372...” A spirit or demon possessing a body is an impure form that makes one sick. Items such as crosses or holy water are employed in its exorcism - to exercise/exorcise the demon and make healthy again - along with the name of the unclean. The same is done today in modern vaccine administration. The holy water is replaced by a vaccine vial, the cross is replaced by a syringe and plunger, the demon's name is replaced by the variant or virus name, and the ritual robes are replaced by white lab coats.  The pandemic was not about a virus and a distinct set of symptoms. Instead it was about inducing archetypical fear and https://www.weforum.org/stories/2020/10/the-rich-got-richer-during-the-pandemic-and-that-s-a-daunting-sign-for-our-recovery/. It was at best https://www.history.com/articles/mysterious-illnesses-mass-hysteria, in the middle a conspiracy of fraud and psychological terror, and at worst a dark magical ritual to induce trauma.  Further evidence of the fraud can be found in reports like this one from the New York Times that discuss the ultra amplification of PCR testing cycles from the low 30s to the mid 40s -“https://absa.org/wp-content/uploads/2020/09/NYT-200829-Your-Coronavirus-Test.pdf” - “In three sets of testing data that include cycle thresholds, compiled by officials in Massachusetts, New York and Nevada, up to 90 percent of people testing positive carried barely any virus…In Massachusetts, from 85 to 90 percent of people who tested positive in July with a cycle threshold of 40 would have been deemed negative if the threshold were 30 cycles.”  Even ‘true' positive tests do not indicate symptoms or disease, or the future development of such, which brings us back to the White House website and the statement about the lab leak: “The virus possesses a biological characteristic that is not found in nature.” This may be true, as per whatever is being assumed to exist, or observed under a microscope, or played with in a computer model, yet it does not prove any disease, especially in https://abcnews.go.com/Health/covid-transmission-asymptomatic/story?id=84599810. *The is the FREE archive.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Have you wondered why having more drug options matters for chronic rhinosinusitis with nasal polyps? In the inaugural episode of our new series, The Itch Review, co-hosts Kortney and Dr. Payel Gupta, along with special guest Dr. Michael Blaiss, unpack the journal article "Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps," published in the New England Journal of Medicine on March 1, 2025. This article is about the Phase III WAYPOINT trial of tezepelumab. Already approved for severe asthma, this once-monthly biologic is now showing promise in chronic rhinosinusitis with nasal polyps (CRSwNP). Over 52 weeks, 408 patients were randomized to receive 210 mg of tezepelumab every four weeks or placebo. Researchers tracked nasal-polyp scores, congestion, sense of smell, and rates of rescue surgery. In this episode, we provide a brief overview of what CRSwNP is, why inflammation drives polyp formation and how blocking TSLP fits into today's biologics options. We'll walk you through the WAYPOINT Phase III design, explain the primary and secondary endpoints, and translate the headline results into what they mean for real-world patients who've exhausted their treatment options. ➡️ Get the infographic here. What we cover in our episode about treating chronic rhinosinusitis with nasal polyps with tezepelumab CRSwNP basics & tezepelumab mechanism of action: How nasal polyps form and why targeting TSLP can reduce inflammation WAYPOINT design: 52-week, placebo-controlled Phase III study in 408 patients  Primary endpoints: Mean change in nasal polyp score and nasal-congestion score Secondary endpoints: Smell recovery, need for rescue surgery or systemic steroids, and quality-of-life measures Why choice matters: Every CRSwNP patient responds differently, and having more treatment options means more chances to find the right fit   Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Dr. Justin Abbatemarco talks with Dr. Jiwon Oh about Bruton Tyrosine Kinase (BTK) Inhibitors and the recent data on tolebrutinib in multiple sclerosis. Read the related article on Tolebrutinib versus Teriflunomide in The New England Journal of Medicine. Read the related article on Tolebrutinib in Nonrelapsing Secondary Progressive MS in The New England Journal of Medicine. Disclosures can be found at Neurology.org. 

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

Ethan Kross shares simple, science-backed tools for managing your emotions. — YOU'LL LEARN — 1) When avoidance is actually helpful 2) Effortless strategies for quickly shifting your mood 3) The emotional regulation framework used by the Navy SEALs Subscribe or visit AwesomeAtYourJob.com/ep1050 for clickable versions of the links below. — ABOUT ETHAN — Ethan Kross, PhD, author of the national bestseller Chatter, is one of the world's leading experts on emotion regulation. An award-winning professor in the University of Michigan's top ranked Psychology Department and its Ross School of Business, he is the Director of the Emotion and Self-Control Laboratory. Ethan has participated in policy discussion at the White House and has been interviewed about his research on CBS Evening News, Good Morning America, Anderson Cooper Full Circle, and NPR's Morning Edition. His research has been featured in The New York Times, The Wall Street Journal, The New Yorker, The New England Journal of Medicine, and Science. He completed his BA at the University of Pennsylvania and his PhD at Columbia University.• Book: Shift: Managing Your Emotions--So They Don't Manage You • Book: Chatter: The Voice in Our Head, Why It Matters, and How to Harness It • Study: “Remotely administered non-deceptive placebos reduce COVID-related stress, anxiety, and depression” with Darwin A. Guevarra, Christopher T. Webster, Jade N. Moros, and Jason S. Moser • Website: EthanKross.com — RESOURCES MENTIONED IN THE SHOW — • Book: The Lincoln Letter: A Peter Fallon Novel (Peter Fallon and Evangeline Carrington) by William Martin • Book: Emotional Agility: Get Unstuck, Embrace Change, and Thrive in Work and Life by Susan David • Book: Man's Search for Meaning by Viktor Frankl • Book: The Amazing Adventures of Kavalier & Clay: A Novel by Michael Chabon • Past episode: 023: The Power of Workplace Humor with Michael KerrSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.